Global Nuclear Medicine Diagnostics Market to reach USD XX billion by 2027
Global Nuclear Medicine Diagnostics Market is valued approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2021-2027. The market is currently expanding due to an increase in the number of cancer cases and increased awareness of nuclear medicine. Radiopharmaceuticals are pharmaceutical formulations that contain radioactive isotopes for diagnostic and therapeutic purposes. They are tiny basic objects that contain a radioactive chemical that is used to treat cancer, as well as cardiac and neurological diseases. For oncology and cancer treatment, traditional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals, which opens up new paths in the radiopharmaceuticals industry. It also serves as a convenient and safer alternative to X-Rays and other external radiation imaging equipment for patients. In applications such as lymphoma and bone metastases, radiopharmaceuticals, often known as nuclear medications, are used. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. Thyroid-related diseases, respiratory diseases, bone diseases, and neurological diseases are among the disorders for which research and studies are undertaken. For instance, in July 2019, French researchers presented data demonstrating the use of hafnium oxide nanoparticle NBTXR3 as a radio enhancer to boost radiation response for soft-tissue sarcoma. PET is a type of radioisotope imaging that employs radioisotopes to diagnose organs. PET is becoming more widely used as a diagnostic tool because it is more accurate than other diagnostic procedures. It is usually combined with X-ray and computed tomography to improve accuracy (CT). The radiopharmaceuticals market is being fueled by a growing demand for rapid and precise diagnosis, as well as a growing demand for better medical solutions. The radiopharmaceuticals market is being fueled by a growing demand for early and precise diagnosis, as well as a demand for better medical solutions. However, radiopharmaceuticals' short half-life hinders their potential adoption, while hospital budget cuts and costly equipment expenses are projected to limit market growth.


The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical analysis of the worldwide Nuclear Medicine Diagnostics market. Due to high investments in R&D and government support for the use of medical isotopes, North America dominated the global market in terms of revenue in 2019. In the same year, Europe's market also accounted for a significant portion of the global market. During the forecast period, the Asia Pacific market is expected to increase at a significant rate. The radiopharmaceuticals market in this region is growing due to an increasing elderly population and increased awareness of nuclear treatments and molecular imaging. This region is also concentrating on the development of radiopharmaceuticals for the diagnosis and treatment of a variety of disorders. For instance, In August 2018, the National Nuclear Agency of Indonesia (BATAN) collaborated with the International Atomic Energy Agency (IAEA) to create innovative radiopharmaceuticals (99mTc-ethambutol) for tuberculosis diagnostics.

Major market player included in this report are:
Cardinal Health
GE Healthcare
Curium Pharma
Lantheus Medical Imaging
Bayer AG
Bracco Imaging SpA
Nordian
Advanced Accelerator Applications
IBA Molecular Imaging
Mallinckrodt PLC
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed inRoute of Administrationation about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
PET radiopharmaceuticals SPECT radiopharmaceuticals
By Modality:
SPECT
PET
Alpha-emitters
Beta-emitters
Brachytherapy
By Application:
Cardiology
Thyroid
Neurology
Oncology
Others
By Procedure:
Oncology
Cardiovascular
Central Nervous System
Endocrine
Skeletal
Gastrointestinal
Genito-urinary
Pulmonary
PET & PET-CT
Therapeutic
Others
By End-User:
Hospitals and diagnostic centers
Research Institutes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Nuclear Medicine Diagnostics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors